Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
study ends around

Description

Summary

Official Title

A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

Details

Keywords

Cutaneous Squamous Cell Carcinoma, High risk, Carcinoma, Squamous Cell Carcinoma, Cemiplimab

Eligibility

Locations

  • UCSF (UCSF) - Helen Diller Family Comprehensive Cancer Center
    San Francisco California 94143-0981 United States
  • Stanford Cancer Institute, Stanford Medicine at Stanford University
    Palo Alto California 94304 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Regeneron Pharmaceuticals
ID
NCT03969004
Phase
Phase 3 research study
Study Type
Interventional
Participants
About 415 people participating
Last Updated